Novel Imaging Modalities For Plexiform Neurofibromas
- Determine whether fludeoxyglucose F 18 positron emission tomography (FDG-PET) and MR
perfusion studies can predict plexiform neurofibroma growth rates in patients with
- Determine whether FDG-PET and MR perfusion studies can predict the likelihood of
response in patients who are undergoing investigational treatment for plexiform
- Identify neuroimaging characteristics that distinguish patients who have responded to
therapy from those who have not after completion of treatment.
- Stratum 1: Patients undergo MR perfusion scan with gadopentetate dimeglumine and
fludeoxyglucose F 18 positron emission tomography (FDG-PET) at baseline and
quantitative MRI evaluation at baseline and 1 year.
- Stratum 2: Patients undergo quantitative MRI, MR perfusion scan with gadopentetate
dimeglumine, and FDG-PET at baseline and 1 year.
PROJECTED ACCRUAL: A total of 48 patients (32 for stratum 1 and 16 for stratum 2) will be
accrued for this study.
Masking: Open Label, Primary Purpose: Diagnostic
Tumor progression as measured by tumor area and volume at 1 year
Michael Fisher, MD
Children's Hospital of Philadelphia
|Children's Hospital of Philadelphia||Philadelphia, Pennsylvania 19104|
|Abramson Cancer Center of the University of Pennsylvania||Philadelphia, Pennsylvania 19104-4283|